


Reply to 06/10/03 Office Action

Claims

1. (Currently amended) A compound of formula I



I

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof,
wherein each R^1 is independently

- a) H,
- b) C_{1-4} alkyl,
- c) C_{1-4} alkyl substituted by a phenyl where the phenyl is optionally substituted with one or two R^2 , or
- d) phenyl, optionally substituted with one or two R^2 ;

R^2 is

- a) halo,
- b) OR^3 ,
- c) CF_3
- d) $C(=O)-NR^4R^5$,
- e) $NH-SO_2-R^6$,
- f) NR^4R^5 ,
- g) $NR^4-C(=O)-R^4$,
- h) $SO_2-NR^4R^5$,
- i) CN, or
- j) NO_2 ;

R^3 is H, C_{1-4} alkyl, or phenyl;

R^4 and R^5 are independently H, C_{1-4} alkyl, or R^4 and R^5 taken together with the attached nitrogen atom to form a ring selected from the group consisting of 1-pyrrolidinyl, 1-piperazinyl and 1-morpholinyl;

R^6 is H or C_{1-4} alkyl;

R^7 is

- a) H, or

Reply to 06/10/03 Office Action

- b) halo,
c) OR^3 ,
d) CF_3
e) $\text{C}(=\text{O})\text{-NR}^4\text{R}^5$,
5 f) $\text{NH-SO}_2\text{-R}^6$,
g) NR^4R^5 ,
h) $\text{NR}^4\text{-C}(=\text{O})\text{-R}^4$,
i) $\text{SO}_2\text{-NR}^4\text{R}^5$,
j) CN, or
10 k) NO_2 ;
 R^8 is
a) H,
b) F,
c) Cl,
15 d) $\text{C}_{1-4}\text{alkyl}$,
e) $\text{C}_{1-3}\text{alkoxy}$,
f) CF_3 ,
g) $\text{C}_{1-4}\text{alkyl}$ substituted by a phenyl wherein the phenyl is optionally substituted with one or two R^2 ,
20 h) phenyl, optionally substituted with one or two R^2 ,
i) OR^3 ,
j) $\text{CO-NR}^4\text{R}^5$,
k) NR^4R^5 ,
l) $\text{NH-SO}_2\text{-R}^6$, or
25 m) NH-CO-R^4 ;

at each occurrence, alkyl and alkoxy is optionally substituted with OH, halo, or NH_2 ; m is 1 to 2; and n is 1-3, or pharmaceutically acceptable salts, prodrugs, and isotopically labeled ~~derivatives~~compounds thereof.

- 30 2. (Original) A compound of claim 1 wherein each R^1 is independently H, methyl, or ethyl.
3. (Original) A compound of claim 1 wherein R^7 is hydrogen.

Reply to 06/10/03 Office Action

4. (Original) A compound of claim 1 wherein R⁸ is hydrogen.
5. (Original) A compound of claim 1 wherein R⁸ is F, OCH₃, or CF₃.
- 5
6. (Original) A compound of claim 1 which is
- (a) (R, R,) 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl
phenyl sulfone hydrochloride,
- (b) (S, S,) 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl
phenyl sulfone hydrochloride,
- 10 (c) (R, S,) 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl
phenyl sulfone hydrochloride, or
- (d) (S, R,) 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl
phenyl sulfone hydrochloride.
- 15
7. (Currently amended) A compound selected from:
- (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- 20 (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
25 octahydroazepino[4,5-b]indole
- (5aS, 10bS)-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aS, 10bS)-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- 30 (5aS, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bS)-6-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3,6-dimethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bS)-3,6-dimethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3,6-dimethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aS, 10bS)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bS)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bS)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bS)-3-ethyl-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bS)-3-ethyl-6-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-1,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bS)-2,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-4,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bS)-5,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

(5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

5

(5aS, 10bS)-1,5,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-2,4,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

10 (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

15

(5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

20

(5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

25 (5aS, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bS)-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

30

(5aS, 10bS)-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bS)-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bS)-3-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aS, 10bS)-3-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bS)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bS)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bS)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bS)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bS)-3-ethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-1-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bS)-2-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-4-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-5-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bS)-1,5-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-2,4-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bS)-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bS)-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-6-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aR, 10bS)-3,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bS)-3,6-dimethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3,6-dimethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3,6-dimethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bS)-3-ethyl-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bS)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bS)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
10 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bS)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-6-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bS)-1,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-2,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-4,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-
25 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-5,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-
10 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-1,5,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-2,4,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-
15 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bS)-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-
30 b]indole
- (5aR, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bS)-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aR, 10bS)-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bS)-9-[(3,4-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3,5-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bS)-3-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bS)-9-[(3-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bS)-3-ethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
5 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- 10 (5aR, 10bS)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
15 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aR, 10bS)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- 20 (5aR, 10bS)-3-ethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole
- (5aR, 10bS)-1-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-
b]indole
- 25 (5aR, 10bS)-2-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-
b]indole
- (5aR, 10bS)-4-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-
b]indole
- (5aR, 10bS)-5-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-
30 b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-
octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-
- 10 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15
- (5aR, 10bS)-1,5-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-2,4-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-
- 25 octahydroazepino[4,5-b]indole
- (5aR, 10bS)-9-[(3-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
- 30 octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bR)-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-
- 10 octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-6-methyl-9-[(4-trifluoromethyl)phenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15
- (5aS, 10bR)-3,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-
- 25 octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3,6-dimethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3,6-dimethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bR)-3,6-dimethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3-ethyl-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bR)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bR)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3-ethyl-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bR)-3-ethyl-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bR)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3-ethyl-6-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aS, 10bR)-1,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-2,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-4,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bR)-5,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-1,5,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bR)-2,4,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bR)-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aS, 10bR)-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aS, 10bR)-3-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aS, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bR)-3-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-3-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

(5aS, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

5 (5aS, 10bR)-3-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-3-ethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

10 (5aS, 10bR)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

15 (5aS, 10bR)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-3-ethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

20 (5aS, 10bR)-3-ethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

25 (5aS, 10bR)-3-ethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aS, 10bR)-1-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

30 (5aS, 10bR)-2-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aS, 10bR)-4-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-5-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-
- 10 octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-
- 20 octahydroazepino[4,5-b]indole
- (5aS, 10bR)-1,5-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-2,4-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-
- 25 octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aS, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aR, 10bR)-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-6-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bR)-3,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bR)-3,6-dimethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bR)-3,6-dimethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-3,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3,6-dimethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aR, 10bR)-3-ethyl-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bR)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bR)-3-ethyl-6-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-6-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bR)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-6-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bR)-1,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bR)-2,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-4,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bR)-5,6-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-4,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-5,6-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-1,5,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bR)-2,4,6-trimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,5,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

(5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2,4,6-trimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

5 (5aR, 10bR)-6-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

10 (5aR, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

15 (5aR, 10bR)-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

20 (5aR, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

25 (5aR, 10bR)-3-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

30 (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(3,4-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bR)-9-[(3,5-difluorophenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-methyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bR)-3-methyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-methoxyphenyl)sulfonyl]-3-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aR, 10bR)-3-methyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bR)-3-ethyl-9-[(4-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(3-fluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bR)-3-ethyl-9-[(3,4-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(3,5-difluorophenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(4-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bR)-3-ethyl-9-[(3-methylphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[(4-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bR)-3-ethyl-9-[(3-methoxyphenyl)sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-3-ethyl-9-[[4-(trifluoromethyl)phenyl]sulfonyl]-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

- (5aR, 10bR)-1-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-2-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 5 (5aR, 10bR)-4-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-5-methyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 10 (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 15 (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 20 (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-4-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-5-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 25 (5aR, 10bR)-1,5-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- (5aR, 10bR)-2,4-dimethyl-9-(phenylsulfonyl)-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole
- 30 (5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

Reply to 06/10/03 Office Action

(5aR, 10bR)-9-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole

(5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-1,5-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole and

5 (5aR, 10bR)-9-[(3-fluorophenyl)sulfonyl]-2,4-dimethyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indole.

8. (Currently Amended) A compound selected from the group consisting of 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl phenyl sulfone; 6-
10 methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl-4-fluorophenyl sulfone; and pharmaceutically acceptable salts thereof, wherein the compound includes an isotopic label.

9. (Original) A compound according to Claim 1 containing an isotope selected from
15 ^3H , ^{11}C , ^{14}C , ^{13}N , ^{15}O , ^{18}F , $^{99\text{m}}\text{Tc}$, ^{123}I , and ^{125}I .

10. (Original) The compound of claim 9, wherein the compound includes at least one atom selected from ^{11}C , ^{13}N , ^{15}O , and ^{18}F .

20 11. (Original) A method of performing positron emission tomography comprising: incorporating an isotopically labeled compound into tissue of a mammal, wherein the isotopically labeled compound is selected from 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl phenyl sulfone and 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl-4-fluorophenyl sulfone; and pharmaceutically
25 acceptable salts thereof, and each compound includes at least one atom selected from ^{11}C , ^{13}N , ^{15}O , and ^{18}F .

12. (Original) A method of performing nuclear magnetic resonance imaging comprising:
30 incorporating a compound into tissue of a mammal, wherein the compound is 6-methyl-1,2,3,4,5,5a,6,10b-octahydroazepino[4,5-b]indol-9-yl-4-fluorophenyl sulfone or a pharmaceutically acceptable salt thereof provided that the fluorine atom is ^{19}F .

Reply to 06/10/03 Office Action

13. (Original) A method for treating a disease or disorder of the central nervous system in a mammal comprising administering a therapeutically effective amount of a compound of formula I as shown in claim 1, or a pharmaceutically acceptable salt thereof, to said mammal.

5

14. (Original) A method for treating a disease or disorder in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising administering a therapeutically effective amount of a compound of formula I as shown in claim 1, or a pharmaceutically acceptable salt thereof.

10

15. (Original) The method of claim 14 wherein the receptor is a 5-HT₆ receptor.

16. (Original) The method of claim 13 or 15 wherein the mammal is a human.

15 17. (Original) The method of claim 13 or 15 wherein said disease or disorder is anxiety, depression, schizophrenia, a stress related disease, panic disorder, a phobia, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, psychosis, paraphrenia, mania, convulsive disorders, personality disorders, migraine headache, drug addiction, alcoholism, obesity, eating disorders, or sleep
20 disorders.

25

18. (Original) The method of claim 13 or 15 wherein the disease or disorder is psychotic, affective, vegetative, and psychomotor symptoms of schizophrenia and the extrapyramidal motor side effects of other antipsychotic drugs.

19. (Original) The method of claim 13 or 15 wherein the disease is anxiety, obesity, depression, or a stress related disease.

20. (Currently amended) The method of claim 13 or 15 wherein said disease or
30 disorder is obesity, depression, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, a stress related disease (~~e.g. general anxiety disorder~~), panic disorder, a phobia, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, a stress induced problem with

Reply to 06/10/03 Office Action

the urinary, gastrointestinal or cardiovascular system (~~e.g., stress incontinence~~), neurodegenerative disorders, autism, chemotherapy-induced vomiting, hypertension, migraine headaches, cluster headaches, sexual dysfunction in a mammal (~~e.g. a human~~), addictive disorder and withdrawal syndrome, an adjustment disorder, an age-associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder due to general medical conditions, attention-deficit hyperactivity disorder, behavioral disturbance (~~including agitation in conditions associated with diminished cognition (e.g., dementia, mental retardation or delirium)~~), bipolar disorder, bulimia nervosa, chronic fatigue syndrome, conduct disorder, cyclothymic disorder, dysthymic disorder, fibromyalgia and other somatoform disorders, generalized anxiety disorder, an inhalation disorder, an intoxication disorder, movement disorder (~~e.g., Huntington's disease or Tardive Dyskinesia~~), oppositional defiant disorder, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder (~~brief and long duration disorders, psychotic disorder due to medical condition, psychotic disorder NOS~~), mood disorder (~~major depressive or bipolar disorder with psychotic features~~), seasonal affective disorder, a sleep disorder, a specific developmental disorder, agitation disorder, stress incontinence such as urge or mixed incontinence, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome or Tourette's syndrome.

21. (Original) A method for modulating 5-HT receptor function, comprising contacting the receptor with an effective inhibitory amount of a compound of formula I as shown in claim 1.

22. (Original) The method of claim 21 wherein the receptor is a 5-HT₆ receptor.

23. (Original) The method of claim 13 or 15 wherein said compound is administered rectally, topically, nasally, orally, sublingually, transdermally or parenterally.

24. (Original) The method of claim 13 or 15 wherein said compound is administered in an amount from about 0.01 to about 150 mg/kg of body weight of said mammal per day.

Reply to 06/10/03 Office Action

25. (Original) The method of claim 13 or 15 wherein said compound is administered in an amount from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
- 5 26. (Original) The method of claim 13 or 15 wherein said compound is administered in an amount from about 1 to about 30 mg/kg of body weight of said mammal per day.